Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "BMC Cancer"
DOI: 10.1186/s12885-019-6303-z
Abstract: The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective… read more here.
Keywords: lymphoma; ruxolitinib; hodgkin lymphoma; mediastinal large ... See more keywords